Health
Dexamethasone use could reduce immune checkpoint inhibitor efficacy in glioblastoma patients – News-Medical.Net
Bottom Line: Among patients with glioblastoma receiving an immune checkpoint inhibitor, those who received the corticosteroid dexamethasone at baseline for cerebral…
Reviewed by Emily Henderson, B.Sc.Nov 25 2020
Bottom Line: Among patients with glioblastoma receiving an immune checkpoint inhibitor, those who received the corticosteroid dexamethasone at baseline for cerebral edema had significantly worse overall survival.
Journal in Which the Study was Published: Clinical Cancer Research, a journal of the American Association for Cancer Research
Author: David A. Reardon, MD, clinical director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute in…
-
General18 hours agoGymnastics club in Berwick shuts down following child safety complaint
-
Noosa News21 hours agoSanta drops in for carols
-
General24 hours agoCritically endangered orchid thrives as NSW Mid North Coast cemetery provides habitat refuge
-
Business23 hours agoThe best Australian stock you’ve never heard of